17.17
Tandem Diabetes Care Inc stock is traded at $17.17, with a volume of 1.58M.
It is up +0.29% in the last 24 hours and up +5.73% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$17.12
Open:
$17.13
24h Volume:
1.58M
Relative Volume:
0.68
Market Cap:
$1.18B
Revenue:
$1.03B
Net Income/Loss:
$-94.55M
P/E Ratio:
-12.25
EPS:
-1.4012
Net Cash Flow:
$-3.64M
1W Performance:
-5.14%
1M Performance:
+5.73%
6M Performance:
-14.79%
1Y Performance:
+8.06%
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care Inc
|
17.17 | 1.17B | 1.03B | -94.55M | -3.64M | -1.4012 |
|
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Upgrade | Truist | Hold → Buy |
| Mar-17-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-23-26 | Upgrade | Lake Street | Hold → Buy |
| Feb-20-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Buy |
| Dec-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-21-25 | Resumed | Stifel | Hold |
| Sep-08-25 | Initiated | Oppenheimer | Outperform |
| Aug-12-25 | Upgrade | Citigroup | Sell → Neutral |
| Aug-07-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
TNDM|Tandem Diabetes Care Inc|Price:17.170|Chg%:+0.050 - TradingKey
Tandem Diabetes Care Inc (TNDM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tandem Diabetes Care (TNDM) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Tandem Diabetes Care (TNDM) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
TNDM|Tandem Diabetes Care Inc|Price:17.120|Chg%:+0.220 - TradingKey
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures - AJMC
Tandem Diabetes Care Inc (TNDM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insulin Pump Maker Moves To Dismiss Wrongful Death Case On Preemption Grounds - Mealey's
3 Healthcare Stocks with Questionable Fundamentals - Yahoo Finance
Tandem Diabetes Care Inc (TNDM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
What Tandem Diabetes Care (TNDM)'s CGM Expansion and New Tubeless Rival Mean For Shareholders - Sahm
Understanding the Setup: (TNDM) and Scalable Risk - Stock Traders Daily
Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Exploring a 60% Potential Upside with Robust Buy Ratings - DirectorsTalk Interviews
Tandem Diabetes Care Inc (TNDM) Shares Surge 6.0% -- What GF Sco - GuruFocus
TNDM6032036 Bond Coupon Profile — Rate & Payments - TradingView
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance UK
Tandem Diabetes Care (0M0F) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Can Tandem Diabetes Care (TNDM) Turn Revenue Beats Into Durable Returns On Capital? - webull.com
When Will Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Become Profitable? - 富途牛牛
Tandem Diabetes Care Inc (TNDM) Shares Surge 4.9% -- What GF Sco - GuruFocus
Form 4 Tandem Diabetes Care Inc For: 17 July By Investing.com - Investing.com Nigeria
Tandem Diabetes Care (TNDM) COO logs RSU vesting, 31,741 shares held after tax withholding - Stock Titan
US875372AE4 Bond Profile — Key Metrics - TradingView
Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss? - Stocktwits
Unpacking Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks - Yahoo Finance
Mizuho Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
TNDM Maintained by Mizuho -- Price Target Lowered to $20.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Boston Scientific (BSX) - The Globe and Mail
Tandem Diabetes Care (TNDM) Expands Abbott Compatibility As Undervalued Narrative Faces A Fresh Test - Sahm
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
Does Libre 3 Plus Integration Expand Tandem’s Interoperability Edge And Bull Case For TNDM? - Yahoo Finance
No Title Or Subtitle Provided To Check - Finimize
Is Tandem Diabetes Care (TNDM) Undervalued Following Its Abbott Libre 3 Plus Expansion? - Yahoo Finance
Tandem’s Expanded Libre 3 Plus Integration Could Be A Game Changer For Tandem Diabetes Care (TNDM) - Sahm
Tandem Diabetes Care (TNDM) Goldman Sachs 46th Annual Global Healthcare Conference summary - Quartr
Tandem Diabetes Care Inc. (TNDM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $17 - Moomoo
Tandem Diabetes Care (TNDM) Stifel 2024 Healthcare Conference Summary - Quartr
Does TNDM Stock Still Deserve a Place in Your Portfolio? - TradingView
Is the Market Underestimating Tandem Diabetes Care, Inc. (TNDM)’s Transition Risks? - Insider Monkey
10 Best Get Rich Quick Stocks to Buy Right Now - Insider Monkey
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility With Abbott's FreeStyle Libre 3 Plus CGM Sensor - Medical Product Outsourcing
Tandem Diabetes Q1 2026 slides: record revenue, profitability returns - Investing.com
TNDMTandem Diabetes Care Inc Options - Finviz
Tandem Diabetes faces earnings test as pay-as-you-go shift weighs - Investing.com
ETFs Investing in Tandem Diabetes Care, Inc. Stocks - TradingView
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Diabetes warning issued over insulin pump error - MSN
Tandem Diabetes Care (TNDM) Expands Compatibility with Abbott's FreeStyle Libre 3 Plus - GuruFocus
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):